|Nom||Titre||Payer||Exercé||Année de naissance|
|Mr. Alain Moussy MBA||Co-Founder, Chairman, President, CEO, MD & Scientific Director||596k||S.O.||S.O.|
|Mr. Laurent Guy MBA||Chief Financial Officer||S.O.||S.O.||S.O.|
|Mr. Christian FASSOTTE||Global Chief Medical Officer||S.O.||S.O.||S.O.|
|Mr. Alexis BERNARD||Head of Veterinary Sales||S.O.||S.O.||S.O.|
|Mr. Harshad KULKARNI||Head of Statistics||S.O.||S.O.||S.O.|
|Dr. Albert Ahn D.V.M.||President of USA Operations||S.O.||S.O.||S.O.|
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
L’ISS Governance QualityScore de AB Science S.A. en date du 1 décembre 2023 est 10. Les scores principaux sont Audit : 10; Société : 9; Droits des actionnaires : 10; Compensation : 10.